Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05386173
Other study ID # FASSprosp
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date January 1, 2021
Est. completion date December 31, 2029

Study information

Verified date November 2023
Source Queen Silvia Children's Hospital, Gothenburg, Sweden
Contact Mats Mellander, Dr, Prof
Phone 0046705530606
Email mats.mellander@vgregion.se
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

In one of the most severe congenital heart defects, hypoplastic left heart syndrome (HLHS), the left ventricle is underdeveloped and the prognosis is worse than in most other heart defects. The underdevelopment can occur gradually during fetal growth caused by a narrowing of the aortic valve. At some international centers, such fetuses are treated with a balloon dilation of the narrowed valve, but there is no scientifically sound evidence that this treatment is effective. The aim of this study is: 1/ to evaluate whether balloon dilation during the fetal period of a narrowed aortic valve can reduce the risk of the left ventricle becoming underdeveloped and the baby being born with a so-called univentricular heart (HLHS); 2/ to investigate whether such treatment improves the prognosis for this group of children with a very complex and severe heart defect and 3/ to also describe side effects and risks in fetuses and mothers of the fetal procedure.


Description:

Routinely collected pre- and postnatal clinical data will be entered into a digital database and echocardiographic examinations will be uploaded to a server. A core lab will measure and analyze all echocardiographic examinations according to protocol. The growth of the left heart structures and the postnatal outcome will be compared between the intervention and non-intervention groups. The decision whether a fetal balloon dilatation shall be attempted is not part of the study protocol. The number of examinations of mother/fetus/infant in this study is not different from the number of examinations that will be recommended for someone choosing not to be part of this study. Participation in the study does not affect the care and treatment mothers and fetuses are receiving during pregnancy, nor how the infant is examined and treated after birth.


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date December 31, 2029
Est. primary completion date December 31, 2029
Accepts healthy volunteers No
Gender All
Age group 23 Weeks to 31 Weeks
Eligibility Inclusion Criteria: A. All of the following echocardiographic criteria need to be satisfied between 23+0 and 31+6 weeks (z-scores according to Schneider et al): 1. Aortic valve stenosis with antegrade flow through the valve 2. Predominantly left-to-right shunt at the atrial level 3. Predominantly retrograde flow in the aortic arch between the first two brachiocephalic vessels 4. Qualitatively depressed left ventricular function 5. Left ventricular end-diastolic diameter Z-score > ±0 6. Left ventricular inlet length in diastole : 1. Gestational age = 24+6: Z-score > ±0 2. Gestational age 25+0 to 27+6: Z-score > -0.75 3. Gestational age = 28+0: Z-score > -1.50 7. Mitral valve diameter in diastole Z-score > -2.0 B. All of the following postnatal treatment options need to be available: 1. Surgical or catheter based aortic valvotomy 2. Ross-Konno surgery 3. Norwood or hybrid stage-one surgery Exclusion Criteria: 1. Any associated cardiac defect except persistent left superior vena cava and coarctation of the aorta 2. Any significant (i.e. that might influence outcome) extracardiac anomaly and/or known chromosomal aberration. Also, if such a condition is present at inclusion but diagnosed only after birth the case will be retrospectively excluded.

Study Design


Intervention

Procedure:
Fetal aortic balloon dilatation
Fetal valvuloplasty will be performed as described in Arzt W, Wertaschnigg D, Veit I, Klement F, Gitter R, Tulzer G. Intrauterine aortic valvuloplasty in fetuses with critical aortic stenosis: experience and results of 24 procedures. Ultrasound Obstet Gynecol. 2011;37:689-695. with minor variations between centers involved. Technical success is defined as improved forward flow and/or new aortic regurgitation.

Locations

Country Name City State
Austria Kinderherzzentrum Linz Linz
Canada The Hospital for Sick Children Toronto Toronto
Finland Department of Paediatric Cardiology, Helsinki University Children's Hospital Helsinki
Germany Pediatric Cardiology - University Hospital Bonn Bonn
Germany Department of Pediatric and Congenital Cardiology, University of Heidelberg Heidelberg
Germany University hospital Technical university, mother- and-child center Munich
Poland Department of Perinatal Cardiology and Congenital Anomalies, Centre of Postgraduate Medical Education. Warsaw
Spain Fetal Medicine Unit, Dept. Obstetrics & Gynecology University Hospital 12 de Octubre Madrid
Sweden Department of Pediatric Cardiology, Skane University Hospital Lund
Sweden Department of pediatric cardiology, Karolinska Institute Stockholm
Sweden Department of Pediatrics, Umeå University Hospital Umeå
United States Congenital Heart Collaborative, Nationwide Children's Hospital Columbus Ohio
United States Fetal Cardiovascular Program, University of California San Francisco San Francisco California

Sponsors (3)

Lead Sponsor Collaborator
Queen Silvia Children's Hospital, Gothenburg, Sweden Sahlgrenska University Hospital, Sweden, Swedish Heart Lung Foundation

Countries where clinical trial is conducted

United States,  Austria,  Canada,  Finland,  Germany,  Poland,  Spain,  Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Primary Transplantation-free survival Transplantation-free survival from fetal diagnosis to 2 years postnatal age with a biventricular circulation without pulmonary hypertension at that time. Absence of pulmonary hypertension is defined as a TR max velocity = 2.8 m/s with no other echocardiographic signs of pulmonary hypertension and/or catheter data showing a mean pulmonary arterial pressure <25 mmHg. Follow-up from study inclusion during fetal life until 2 years postnatal age
Secondary Intervention-related fetal death Intervention-related fetal death (defined as fetal death within 24 hours of procedure) From the time of fetal intervention until 24 hours after the intervention
Secondary Fetal death not directly related to the intervention Fetal death not directly related to the intervention, except termination of pregnancy From 24 hours after fetal intervention until fetal death, up to 20 weeks after study inclusion.
Secondary Maternal complications to fetal intervention procedure Maternal complications to procedure requiring intensive care or resulting in maternal death From time of fetal intervention until 24 hours after the intervention
Secondary Preterm delivery Preterm delivery before 37 weeks gestational age From time of fetal intervention until 37 weeks gestational age, maximum 14 weeks
Secondary Fetal left heart growth Fetal left heart growth as measured with dimensions expressed a z-scores of the mitral valve diameter, left ventricular inlet length and aortic valve diameter From the date of study inclusion until just before the first postnatal catheter or surgical intervention, or death, whichever comes first, total time frame 7 months
See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT04992793 - Paediatric Brain Injury Following Cardiac Interventions
Recruiting NCT05213598 - Fontan Associated Liver Disease and the Evaluation of Biomarkers for Disease Severity Assessment
Completed NCT04136379 - Comparison of Home and Standard Clinic Monitoring of INR in Patients With CHD
Completed NCT04814888 - 3D Airway Model for Pediatric Patients
Recruiting NCT04920643 - High-exchange ULTrafiltration to Enhance Recovery After Pediatric Cardiac Surgery N/A
Completed NCT05934578 - Lymphatic Function in Patients With Fontan Circulation: Effect of Physical Training N/A
Recruiting NCT06041685 - Effect of Local Warming for Arterial Catheterization in Pediatric Anesthesia N/A
Recruiting NCT05902013 - Video Laryngoscopy Versus Direct Laryngoscopy for Nasotracheal Intubation N/A
Not yet recruiting NCT05687292 - Application of a Clinical Decision Support System to Reduce Mechanical Ventilation Duration After Cardiac Surgery
Not yet recruiting NCT05524324 - Cardiac Resynchronization Therapy in Adult Congenital Heart Disease With Systemic Right Ventricle: RIGHT-CRT N/A
Completed NCT02746029 - Cardiac Murmurs in Children: Predictive Value of Cardiac Markers
Completed NCT02537392 - Multi-micronutrient Supplementation During Peri-conception and Congenital Heart Disease N/A
Completed NCT03119090 - Fontan Imaging Biomarkers (FIB) Study
Recruiting NCT02258724 - Swiss National Registry of Grown up Congenital Heart Disease Patients
Completed NCT01966237 - Milrinone Pharmacokinetics and Acute Kidney Injury
Terminated NCT02046135 - Sodium Bicarbonate to Prevent Acute Kidney Injury in Children Undergoing Cardiac Surgery Phase 2
Recruiting NCT01184404 - Bosentan Improves Clinical Outcome of Adults With Congenital Heart Disease or Mitral Valve Lesions Who Undergo CArdiac Surgery N/A
Completed NCT01548950 - Drug Therapy and Surgery in Congenital Heart Disease With Pulmonary Hypertension N/A
Completed NCT01178710 - Effect of Simvastatin on Cardiac Function N/A